BCL-XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME

The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs. La présente inve...

Full description

Saved in:
Bibliographic Details
Main Authors TAO, ZHI-FU, SULLIVAN, GERARD M, CULLEN, STEVE C, BENNETT, NATHAN B, HAIGHT, ANTHONY R, ACKLER, SCOTT L, BOGHAERT, ERWIN R, FREY, ROBIN R, WANG, XILU, SONG, XIAOHONG, WELCH, DENNIE S, SHEN, XIAOQIANG, KUNZER, AARON R, WENDT, MICHAEL D, MARIN, VIOLETA L, JUDD, ANDREW S, DOHERTY, GEORGE, SOUERS, ANDREW J
Format Patent
LanguageEnglish
French
Published 16.06.2016
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs. La présente invention concerne des inhibiteurs de Bcl-xL ayant une faible perméabilité cellulaire, des conjugués anticorps-médicament (ADC) comprenant les inhibiteurs, des synthons utiles pour la synthèse des ADC, des compositions comportant les inhibiteurs ou les ADC, et divers procédés d'utilisation des inhibiteurs et des ADC.
Bibliography:Application Number: CA20152970155